Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

San Diego-Based Fate Therapeutics To Host Q4/Full Year 2020 Earnings & Corporate Update Conference Call Wednesday, February 24, 2021

By John F. Heerdink, Jr.

San Diego-based Fate Therapeutics, Inc. (NASDAQ: FATE) has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease.

Scott Wolcho – President & Chief Executive Officer at Fate Therapeutics

Today, Fate announced that the Company will host a conference call and live audio webcast on Wednesday, February 24, 2021 at 5:00 p.m. ET to report its fourth quarter and full year 2020 financial results and provide a corporate update. In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 6368962. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

In the meantime, to keep up with Fate’s progress and to learn more consider visiting and bookmarking the Fate Therapeutics (FATE) Page within the VP Watchlist


Post View Count : 448


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us